<DOC>
	<DOCNO>NCT01332318</DOCNO>
	<brief_summary>This study multi center , randomize , double blind , active placebo control , parallel group study assess simulated drive performance XP13512 treat subject Restless Legs Syndrome ( RLS ) . Eligible subject randomize receive daily dose placebo ( 2 group ) , XP13512 1200 mg , XP13512 1800 mg 16 day . On Day 16 , one placebo group also receive one 50 mg dose diphenhydramine ( DPH ) ass effect agent know sedative property , 3 group receive DPH placebo .</brief_summary>
	<brief_title>Simulated Driving Study Restless Legs Syndrome</brief_title>
	<detailed_description>This study multicenter , randomize , double blind , active placebo control , parallel group study . Eligible subject randomize 1:1:1:1 ratio 1 follow 4 treatment group : A ) XP13512 Placebo + Diphenhydramine Placebo ( Pbo ) B ) XP13512 1200 mg/day + Diphenhydramine Placebo ( 1200 mg ) C ) XP13512 1800 mg/day + Diphenhydramine Placebo ( 1800 mg ) D ) XP13512 Placebo + 50 mg Diphenhydramine ( Pbo/DPH )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<criteria>Men woman 21 65 year age fluent English ; Subjects RLS , base IRLSSG Diagnostic Criteria ; Currently license experience driver driven average 3 times/week past 3 year ; Able successfully complete 5 minute practice simulate drive test Screening ; History RLS symptoms least 15 night prior month , treatment , frequency symptom treatment start ; Total RLS severity score 15 great IRLS Rating Scale ; Documented RLS symptoms least 4 7 consecutive evenings/nights Discontinuation treatment RLS ( e.g. , opioids , benzodiazepine , dopamine agonist and/or gabapentin ) least 2 week prior Screening ; Body Mass Index 34 ; Estimated creatinine clearance least 60 mL/min ; Agreed maintain abstinence alcohol smoke throughout entire study period ; Agreed maintain abstinence caffeine midnight day prior end Visit ( Visits 2 4 ) . A sleep disorder ( e.g. , sleep apnea ) RLS may significantly affect assessment RLS ; Current use sleep medication sedate medication ; Current use CNS stimulant ; Neurologic disease movement disorder ; Other medical condition could affect RLS assessment ; Significant medical history may impair psychomotor coordination ; Subjects clinically significant unstable medical condition ; Serum ferritin level 20 ng/mL ; Subjects currently suffer moderate severe depression use Diagnostic Statistical Manual Mental Disorders Treatment IV ( DSM IV TR ) ; Subjects history substance abuse ( alcohol drug ) substance dependence within 12 month prior enrollment ; Shift worker subject normal day/night sleep cycle ; Subjects smoke average great one half pack cigarette ( nicotine equivalent ) per day within 30 day Screening Visit ; Subjects consume average &gt; 5 cup ( i.e. , 40 ounce ) caffeinated beverage per day within 20 day Screening Visit ; Subjects history allergy gabapentin , diphenhydramine , XP13512 excipients</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>